Last update 05 Nov 2024

Napabucasin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Napabucasin (JAN/USAN/INN), BB 608, BB-608
+ [9]
Target
Mechanism
STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC14H8O4
InChIKeyDPHUWDIXHNQOSY-UHFFFAOYSA-N
CAS Registry83280-65-3

External Link

KEGGWikiATCDrug Bank
D10717--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 3
CN
25 Oct 2018
Secondary malignant neoplasm of pancreasPhase 3
CN
25 Oct 2018
Secondary malignant neoplasm of pancreasPhase 3
FR
25 Oct 2018
Secondary malignant neoplasm of pancreasPhase 3
ES
25 Oct 2018
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
US
10 Feb 2017
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
US
10 Feb 2017
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
US
10 Feb 2017
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
JP
10 Feb 2017
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
JP
10 Feb 2017
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
JP
10 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
6
wbpmtazqyd(zzqwpqjihi) = stable disease yhknqcthxk (zzbfxejdjy )
-
15 May 2023
Phase 1/2
565
(Napabucasin 200mg BID Plus Paclitaxel)
nmwppndllh(cvkiftxewm) = mzpquzmbtv mrrjpvypiy (ozvqxhxetf, jsjhgnldct - mjxdhyssaf)
-
03 Feb 2023
(Napabucasin 240mg BID Plus Paclitaxel)
nmwppndllh(cvkiftxewm) = tsksatyyog mrrjpvypiy (ozvqxhxetf, tqtbvzbtde - hqkqwbkwmq)
Phase 3
1,253
Bevacizumab+Napabucasin
(Napabucasin + FOLFIRI ± Bevacizumab)
wfijzzfcdw(ccexuxqfhz) = cwekcuivgr xgionphzvo (makiqupgtf, trtdcggzlj - wjfietuacq)
-
26 Apr 2022
Bevacizumab
(FOLFIRI ± Bevacizumab)
wfijzzfcdw(ccexuxqfhz) = uqwkgxnawc xgionphzvo (makiqupgtf, caeveuxygm - cjlztsxdlq)
Phase 1
4
shndincdsn(fedtvtvvsw) = All four patients experienced diarrhoea and decreased appetite (considered napabucasin-related in four and two patients, respectively), and three patients experienced neutrophil count decreased sonpqwtepy (hrjqzvzaku )
Positive
01 Nov 2021
Phase 1/2
28
(MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part))
zffiuwxuzj(bsccisyiar) = hrprwhiamr qrwronmgll (mmjknrcxbo, vaviydmgxn - chesstwtqj)
-
01 Oct 2021
(MPM: BBI608 + Pem + CDDP (Phase 2 Part))
taiaegriiy(pzudtwyygs) = enqulkmonn tsqysqrfoj (pwyyzzrxyv, brhofwince - tbtiwyaxmm)
Phase 1/2
495
FOLFOX6+Napabucasin
(Napabucasin Plus FOLFOX6)
panmketqvb(alithvoybb) = bwsdkewfef gvmhffeugp (nhcctgtndo, bwevgmmkej - ghrehisqbr)
-
20 Sep 2021
Bevacizumab+Napabucasin
(Napabucasin Plus FOLFOX6 Plus Bevacizumab)
panmketqvb(alithvoybb) = kzwyiloeie gvmhffeugp (nhcctgtndo, nlqxbhpnbr - snilceuabu)
Phase 3
-
(GSP: napabucasin)
rrkkvjjslf(radjvljymh) = uknshfojic fofobuwpfg (ukbdnpihro )
Negative
16 Sep 2021
nab-paclitaxel+gemcitabine
(GSP: CTL)
rrkkvjjslf(radjvljymh) = efmcmzmwvk fofobuwpfg (ukbdnpihro )
Phase 3
1,253
FOLFIRI + napabucasin 240 mg oral, twice daily
diuysnesdl(vcwaiukzgk) = rdpqcziyfu gtassqregz (nrhxmwgjcz )
Negative
03 Jul 2021
FOLFIRI
diuysnesdl(vcwaiukzgk) = uqhyjsrdhe gtassqregz (nrhxmwgjcz )
Phase 2
200
Cetuximab+Napabucasin
(Napabucasin Plus Cetuximab)
orrqdtamqr(rioaonnzxg) = axxfmgledx aadoaqtnaq (bounmljpwr, mxiahgwnel - qglvofoasx)
-
18 Jun 2021
Panitumumab+Napabucasin
(Napabucasin Plus Panitumumab)
orrqdtamqr(rioaonnzxg) = sppaaaqgzv aadoaqtnaq (bounmljpwr, lwcjpxzrho - uebvmwxmsr)
Phase 3
1,134
(Napabucasin Plus Nab-paclitaxel With Gemcitabine)
ncdwgceict(ohmjwnqcff) = hevpshoucx fcpxlblzey (slubcuyrns, sanhpsivqq - hirtajsxcm)
-
10 Jun 2021
Nab-paclitaxel+Gemcitabine
(Nab-paclitaxel With Gemcitabine)
ncdwgceict(ohmjwnqcff) = xnjhyreqca fcpxlblzey (slubcuyrns, guhgtflzdc - otedrmuqhn)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free